[{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"||GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Jeong-Ho Chae","sponsor":"Ybrain Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Jeong-Ho Chae","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeong-Ho Chae \/ Ybrain Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Jeong-Ho Chae \/ Ybrain Inc."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute on Aging","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ National Institute on Aging"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Unity Health Toronto | Centre for Addiction and Mental Health | McMaster University | Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | ","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Unity Health Toronto | Centre for Addiction and Mental Health | McMaster University | Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | ","highestDevelopmentStatusID":"11","companyTruncated":"Nova Scotia Health Authority \/ Unity Health Toronto | Centre for Addiction and Mental Health | McMaster University | Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | "},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Municipal Hospital of Traditional Chinese Medicine","sponsor":"Shanghai Mental Health Center | Xuhui Central Hospital, Shanghai | Shanghai Huangpu District Mental Health Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shanghai Municipal Hospital of Traditional Chinese Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Municipal Hospital of Traditional Chinese Medicine \/ Shanghai Mental Health Center | Xuhui Central Hospital, Shanghai | Shanghai Huangpu District Mental Health Center","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Municipal Hospital of Traditional Chinese Medicine \/ Shanghai Mental Health Center | Xuhui Central Hospital, Shanghai | Shanghai Huangpu District Mental Health Center"}]

Find Clinical Drug Pipeline Developments & Deals for Esertia

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 23, 2019

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          Shanghai Municipal Hospital of Traditional Chinese Medicine

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Shanghai Municipal Hospital of Traditional Chinese Medicine

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Undisclosed

                          Sponsor : Shanghai Mental Health Center | Xuhui Central Hospital, Shanghai | Shanghai Huangpu District Mental Health Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 19, 2023

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Shanghai Mental Health Center | Xuhui Central Hospital, Shanghai | Shanghai Huangpu District Mental Health Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : At the Day 3 primary endpoint, SAGE-217/BIIB125 (Zuranolone), investigational oral neuroactive steroid GABA-A receptor-positive allosteric modulator, 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction i...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 16, 2022

                          Lead Product(s) : Zuranolone,Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Biogen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Shanghai Mental Health Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Shanghai Mental Health Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 06, 2021

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase IV

                          Sponsor : Unity Health Toronto | Centre for Addiction and Mental Health | McMaster University | Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan |

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 23, 2021

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Unity Health Toronto | Centre for Addiction and Mental Health | McMaster University | Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan |

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 13, 2021

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : National Institute on Aging

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Jeong-Ho Chae

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Jeong-Ho Chae

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 09, 2020

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Ybrain Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          University Health Network, Toronto

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          University Health Network, Toronto

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase III

                          Sponsor : Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | Simon Fraser University | Unity Health Toronto | Baycrest | Centre for Addiction and M

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 14, 2019

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Queen's University | University of Ottawa | University of British Columbia | University of Calgary | McGill University | Dalhousie University | University of Michigan | Simon Fraser University | Unity Health Toronto | Baycrest | Centre for Addiction and M

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Shanghai Mental Health Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Shanghai Mental Health Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 07, 2019

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 07, 2017

                          Lead Product(s) : Escitalopram Oxalate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank